A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

Published:2012-04-19 Issue:10 Volume:106 Page:1598-1604
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Boss D S,Glen H,Beijnen J H,Keesen M,Morrison R,Tait B,Copalu W,Mazur A,Wanders J,O'Brien J P,Schellens J H M,Evans T R J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012154.pdf

Reference37 articles.

1. Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P (2009) Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther 9: 1583–1598

2. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346

3. Dvorak HF (2005) Angiogenesis: update 2005. J Thromb Haemost 3: 1835–1842

4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

5. Eskens FA, Verweij J (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42: 3127–3139

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hand-Foot Syndrome: Highlighting Adverse Effect Management and Patient Education in the Age of Multikinase Inhibitors;Clinical Thyroidology®;2024-09-01

2. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

3. Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib;Molecular and Clinical Oncology;2024-07-10

4. Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights;Pragmatic and Observational Research;2024-06

5. Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A;European Journal of Pharmaceutical Sciences;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3